Mergers and acquisitions in the pharmaceutical industry are not only a positive for the company that has made a bid for another company, but it is also good for the industry as a whole because of increases in efficiency across the entire field, according to Atlas Venture partner Bruce Booth.
Bristol-Myers Squibb Co. offered to divest Celgene Corp.’s psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.
Bayer shares fell by as much as 5 percent after a California couple were awarded more than $2 billion in the largest U.S. jury penalty over allegations the company’s Roundup weed killer causes cancer.
The U.S. patent office rejected a filing by Alvogen Pine Brook for a review challenging patents on Celgene’s blockbuster myeloma drug Revlimid.
Roche is buying U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion after developments in this area convinced the Swiss drugmaker to “step up”, Chief Executive Severin Schwan said.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
More than 100 Boston-area employees from two pharma companies are getting pink slips. Roche and Forma Therapeutics filed WARN notices with the state of Massachusetts.
Merck & Co.’s cancer immumotherapy Keytruda compiled sales that topped $2 billion in a quarter for the first time, exceeding Wall Street’s lofty estimates and sending the company’s shares up.
Pfizer is ending five preclinical programs in the biosimilar area and cutting 150 positions in Lake Forest, Illinois and in Chennai, India.
Bankers are diagnosing another robust year for U.S. healthcare lending as the first two big loans of 2019 include the largest-ever tie-up in the pharmaceutical sector, and more are expected.